Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Behind the Study: Targeting Lipid Metabolism in Treatment of Ovarian Cancer

Oncotarget

September 12, 2022
Dr. Glenn Simmons Jr. from Cornell University College of Veterinary Medicine, and Dr. Stefani Thomas from University of Minnesota School of Medicine, detail a recent review they co-authored that was published by Oncotarget, entitled, “Targeting lipid metabolism in the treatment of ovarian cancer.” continue reading »

Oncotarget | Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma

News

September 8, 2022
PRESS RELEASE: A new research paper was published in Oncotarget, entitled, “Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.” continue reading »

Immunotherapy Response Predicted by Machine Learning & Gut Microbiomes

Oncotarget

August 31, 2022
Researchers investigated common gut microbiome features of response among immunotherapy patients with different advanced-stage cancers. continue reading »

Epigenetics and Immunotherapy Combined Fights Rare Lymphoma

Oncotarget

August 23, 2022
In a new Oncotarget study, researchers assessed an epigenetic and immunotherapy treatment regimen among patients with blastic mantle cell lymphoma (bMCL). continue reading »

Oncotarget | Kinase Activity in Renal Cell Carcinoma, Benign Renal Tissue and in Response to Tyrosine Kinase Inhibitors

Oncotarget

August 17, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 4, 2022, entitled, “Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.” continue reading »